Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months.

No abstract available

ErratumFor

Dermatol Ther (Heidelb). 2025 Feb;15(2):381-394. doi: 10.1007/s13555-025-01342-0.

Article info

Journal issue:

Doi:

10.1007/s13555-025-01420-3

More resources:

Springer

Full Text Sources